ArticleMuscle & nerve2016
Absence of anti-HMG-CoA reductase autoantibodies in severe self-limited statin-related myopathy.
Article in Muscle & nerve, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- Anti-HMGCR-Antibody-Positive Statin-Induced Myositis: A Pilot Case Series on Treatment with Bempedoic Acid and Immunosuppressive Therapy.Antibodies (Basel, Switzerland) · 2025Article
- [Statin intolerance-Statin tolerance].Innere Medizin (Heidelberg, Germany) · 2023Review
- Narrative review of autoantibodies in idiopathic inflammatory myopathies.Annals of translational medicine · 2023Review
- Statin-Induced Immune-Mediated Necrotizing Myopathy Resulting in Proximal Muscle Weakness.Journal of medical cases · 2023Article
- Efficacy and Safety of High-Dose Immunoglobulin-Based Regimen in Statin-Associated Autoimmune Myopathy: A Multi-Center and Multi-Disciplinary Retrospective Study.Journal of clinical medicine · 2020Article
- Neuromuscular Complications of Statin Therapy.Current neurology and neuroscience reports · 2020Review
- Treatment experience of Taiwanese patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase myopathy.The Kaohsiung journal of medical sciences · 2020Article
- Statin Intolerance Clinical Guide 2018.Journal of atherosclerosis and thrombosis · 2020Article
- Statin-Associated Autoimmune Myopathy: Current Perspectives.Therapeutics and clinical risk management · 2020Review
- Immune-mediated necrotizing myopathy due to statins exposure.Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology · 2018Article
- Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations.Expert review of clinical immunology · 2018Review
- Which nonautoimmune myopathies are most frequently misdiagnosed as myositis?Current opinion in rheumatology · 2017Review
- Point-Counterpoint: SLCO1B1 Genotyping for Statins.South Dakota medicine : the journal of the South Dakota State Medical Association · 2017Article
- Anti-HMGCR antibodies demonstrate high diagnostic value in the diagnosis of immune-mediated necrotizing myopathy following statin exposure.Immunologic research · 2017Article
- Statin-Associated Muscle Adverse Events: Update for clinicians.Sultan Qaboos University medical journal · 2016Review
- Spectrum of immune-mediated necrotizing myopathies and their treatments.Current opinion in rheumatology · 2016Review
- Anti-HMGCR Myopathy.Journal of neuromuscular diseasesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
introductionPatients with self-limited statin-related myopathy improve spontaneously when statins are stopped. In contrast, patients with statin-associated autoimmune myopathy have autoantibodies recognizing 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR) and usually require immunosuppressive therapy to control their disease. On initial presentation, it can sometimes be difficult to distinguish between these 2 diseases, as both present with muscle pain, weakness, and elevated serum creatine kinase (CK) levels. The goal of this study was to determine whether patients with severe self-limited statin-related myopathy also make anti-HMGCR autoantibodies.
methodsWe screened 101 subjects with severe self-limited cerivastatin-related myopathy for anti-HMGCR autoantibodies.
resultsNo patient with severe self-limited cerivastatin-related myopathy had anti-HMGCR autoantibodies.
conclusionAnti-HMGCR autoantibody testing can be used to help differentiate whether a patient has self-limited myopathy due to cerivastatin or autoimmune statin-associated myopathy; these findings may apply to other statins as well. Muscle Nerve 54: 142-144, 2016.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.